N=1 After 40

Not run · August 2026

DIHEXA

I considered it for cognition and neuroplasticity, then decided the evidence and safety record did not justify becoming the experiment. A personal research decision, not medical advice, prescribing, sourcing guidance, or an instruction to copy.

Decision: I did not run DIHEXA. The possible upside remains preclinical, direct human evidence is absent, a foundational paper carries an expression of concern, and the principal HGF/c-Met mechanism paper was retracted.

The Decision

Why I considered it

DIHEXA is discussed as something different from an acute stimulant. The interesting claim is structural: support learning and memory by promoting dendritic spines and synaptic connectivity. If that claim translated cleanly to humans, it would sit directly in the cognition and healthy-aging lane I care about.

Why I passed

The confidence required to manipulate a growth-factor pathway should be higher than the confidence required to try an ordinary supplement. Here, the human dose, pharmacokinetics, adverse-event profile, and long-term safety record are not established. At the same time, the most important papers supporting the original story now carry formal research-integrity warnings. The uncertainty is not a missing detail; it is the central fact.

The asymmetry

The expected benefit is speculative and difficult to measure in one healthy person. The possible downside is also uncertain, but it touches a biologically powerful pathway involved in cell survival, proliferation, migration, and angiogenesis. That does not establish that DIHEXA causes cancer. It does mean the absence of long-term safety data matters more, not less.

What could reopen the decision

I would reconsider if DIHEXA itself developed credible human pharmacokinetic and safety data, independent groups reproduced the proposed mechanism, and controlled human studies showed a meaningful cognitive signal. Anecdotes or a cleaner-looking vendor certificate would not resolve the biological uncertainty.

Evidence Review

What it is

DIHEXA, also called PNB-0408, is a metabolically stabilized molecule derived from angiotensin IV. It was developed as a possible procognitive or antidementia candidate and studied primarily in cells and rodents.

The proposed mechanism

The familiar explanation is that DIHEXA binds hepatocyte growth factor, or HGF, and increases signaling through its c-Met receptor. That pathway can engage downstream signaling connected to neuronal survival, dendritic-spine formation, and synaptic plasticity. The problem is that the 2014 paper supplying much of the direct evidence for that HGF/c-Met account was formally retracted in April 2025.

What the animal evidence says

A 2013 rat study reported brain exposure, synaptogenic activity, and improved maze performance in scopolamine-treated and aged animals. That paper received an expression of concern in 2021. A separate 2021 mouse study reported improved spatial learning and changes in PI3K/AKT signaling in an Alzheimer’s model, so the positive record is not limited to a single publication. But it remains preclinical. A 2024 study in a Huntington’s-like rat model found no protection against the induced cognitive, motor, or pathological deficits.

The human evidence gap

I could not find a registered clinical trial testing DIHEXA itself in humans. That leaves no validated human dose, no direct dose-response relationship, no characterized interaction profile, and no long-term adverse-event or carcinogenicity record. Human work on a related molecule cannot be treated as if it establishes the safety or efficacy of DIHEXA sold through research channels.

The c-Met concern

HGF/c-Met signaling is not inherently harmful; it has normal roles in tissue repair, development, and neural biology. It is also a major oncology pathway. Hyperactive or dysregulated c-Met signaling is associated with tumor growth, invasion, metastasis, and treatment resistance across multiple cancers. That is a mechanistic concern, not proof that DIHEXA initiates cancer. Without direct human exposure and long-term safety data, however, the concern cannot be sized with confidence.

Sources